Illumina (NASDAQ:ILMN) Price Target Raised to $210.00 at TD Cowen

Illumina (NASDAQ:ILMN) had its price objective upped by TD Cowen from $192.00 to $210.00 in a report published on Friday,Benzinga reports. They currently have a hold rating on the life sciences company’s stock.

Several other analysts have also recently weighed in on the stock. Citigroup lifted their price objective on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research note on Monday, May 4th. Royal Bank Of Canada raised their target price on shares of Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a report on Friday. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target for the company in a research report on Thursday, May 14th. Evercore reiterated an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. Finally, Leerink Partners increased their price target on Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. Nine research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $175.47.

Illumina Stock Performance

Shares of NASDAQ ILMN opened at $205.10 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The firm has a market cap of $31.03 billion, a price-to-earnings ratio of 38.26, a P/E/G ratio of 3.03 and a beta of 1.47. The stock’s fifty day moving average price is $176.70 and its two-hundred day moving average price is $147.24. Illumina has a one year low of $88.00 and a one year high of $205.93.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 30.54% and a net margin of 18.36%.The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the firm earned $1.19 earnings per share. The company’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts forecast that Illumina will post 5.22 EPS for the current year.

Insider Buying and Selling

In other news, Director Keith A. Meister sold 235,000 shares of Illumina stock in a transaction on Monday, June 1st. The stock was sold at an average price of $163.63, for a total value of $38,453,050.00. Following the transaction, the director owned 2,830,452 shares in the company, valued at approximately $463,146,860.76. This trade represents a 7.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Christensen Jakob Wedel sold 700 shares of the business’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total value of $97,328.00. Following the transaction, the senior vice president directly owned 15,056 shares of the company’s stock, valued at $2,093,386.24. This trade represents a 4.44% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 1,003,769 shares of company stock worth $155,710,908. 2.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Insight Wealth Strategies LLC acquired a new stake in shares of Illumina in the 2nd quarter valued at approximately $6,062,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in shares of Illumina during the 2nd quarter valued at approximately $223,000. FNY Investment Advisers LLC increased its position in Illumina by 30.0% during the 2nd quarter. FNY Investment Advisers LLC now owns 650 shares of the life sciences company’s stock worth $114,000 after purchasing an additional 150 shares in the last quarter. Elevation Wealth Partners LLC increased its position in Illumina by 52.5% during the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock worth $43,000 after purchasing an additional 84 shares in the last quarter. Finally, PensionDanmark Pensionsforsikringsaktieselskab lifted its stake in Illumina by 9.0% in the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 37,664 shares of the life sciences company’s stock valued at $6,622,000 after purchasing an additional 3,100 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q2 results exceeded expectations: Illumina reported $1.16 billion in revenue, up approximately 9.4%–9.5% year over year, while non-GAAP diluted EPS of $1.31 topped the $1.23 consensus estimate. Clinical demand and NovaSeq X placements were key growth drivers. Illumina Q2 financial results
• Positive Sentiment: Full-year guidance was raised: Management increased fiscal 2026 non-GAAP EPS guidance to $5.30–$5.40 and revenue guidance to approximately $4.60–$4.64 billion, modestly ahead of analyst expectations. Illumina outlook
• Positive Sentiment: Analysts raised price targets: JPMorgan lifted its target to $230 and maintained an “overweight” rating; Stifel raised its target to $225 and assigned a “buy” rating. TD Cowen increased its target to $210 but retained a “hold” rating. These revisions signal greater confidence in Illumina’s earnings outlook, although targets vary considerably.
• Positive Sentiment: AI and drug-discovery opportunities remain a catalyst: CEO Jacob Thaysen highlighted genomic medicine and artificial intelligence applications in life sciences. Eli Lilly also joined Illumina’s Billion Cell Atlas alliance, which aims to create large-scale genomic datasets for identifying disease mechanisms and drug targets. Eli Lilly joins Billion Cell Atlas
• Neutral Sentiment: Investors are taking profits near record levels: With ILMN trading close to its one-year high, the strong results may have prompted a “sell-the-news” response as investors sought evidence of further upside beyond the guidance increase.
• Negative Sentiment: China and margins remain concerns: Greater China revenue declined 12%, while full-year non-GAAP operating-margin guidance remained unchanged at 23.4%–23.6%. Management also expects NovaSeq X instrument-placement growth to moderate year over year in the second half. Illumina China and margin analysis
• Negative Sentiment: Insider selling may add pressure: Reported insider activity over the past six months included 41 sales and one purchase, though such transactions may reflect scheduled or personal portfolio activity rather than a direct view of fundamentals.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.